Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glassia for Steroid Non-responsive Acute GVHD
NCT01523821Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2013
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of alpha-1-proteinase inhibitor in Acute Graft-Versus-Host Disease (aGVHD), sponsored by Fred Hutchinson Cancer Center. Started Oct 2013; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
Acute Graft-Versus-Host Disease (aGVHD)
Beyond the preview
Go deeper on NCT01523821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01523821.